<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Heart failure; ACE inhibitors: heart failure; Heart failure: ACE inhibitors; Beta-adrenoceptor blocking drugs: heart failure; Spironolactone: heart failure; Heart failure: vasodilators; Digoxin: heart failure; Diuretics: heart failure" /><meta name="IX" content="Heart failure; ACE inhibitors: heart failure; Heart failure: ACE inhibitors; Beta-adrenoceptor blocking drugs: heart failure; Spironolactone: heart failure; Heart failure: vasodilators; Digoxin: heart failure; Diuretics: heart failure" /><title>Heart failure: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1123-heart-failure.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1123-heart-failure.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1123-heart-failure.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a> &gt; <a href="PHP1034-hypertension-and-heart-failure.htm">2.5 Hypertension and heart failure</a> &gt; <a href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">2.5.5 Drugs affecting the renin-angiotensin system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm" title="Previous: 2.5.5 Drugs affecting the renin-angiotensin system">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm" title="Next: 2.5.5.1 Angiotensin-converting enzyme inhibitors">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Heart failure</h1><?highlighter on?><div id="pC" class="jN"><p>Drug treatment of heart failure associated with a reduced left ventricular ejection fraction (left ventricular systolic dysfunction) is covered below; optimal management of heart failure with a preserved left ventricular ejection fraction has not been established.</p><p>The treatment of chronic heart failure aims to relieve symptoms, improve exercise tolerance, reduce the incidence of acute exacerbations, and reduce mortality. An <strong>ACE inhibitor</strong>, titrated to a ‘target dose’ (or the maximum tolerated dose if lower), together with a <strong>beta-blocker</strong>, form the basis of treatment for all patients with heart failure due to left ventricular systolic dysfunction.</p><p>An ACE inhibitor (<a href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm">section 2.5.5.1</a>) is generally advised for patients with asymptomatic left ventricular systolic dysfunction or symptomatic heart failure. An <strong>angiotensin-II receptor antagonist</strong> (<a title="sub-sub-section: Angiotensin-II receptor antagonists" href="PHP1205-angiotensin-ii-receptor-antagonists.htm">section 2.5.5.2</a>) may be a useful alternative for patients who, because of side-effects such as cough, cannot tolerate ACE inhibitors; a relatively high dose of the angiotensin-II receptor antagonist may be required to produce benefit. Candesartan, an angiotensin-II receptor antagonist, can also be added to an ACE inhibitor and a beta-blocker in patients who continue to remain symptomatic (particularly in those with mild to moderate heart failure).</p><p>The beta-blockers bisoprolol and carvedilol (<a title="section: Beta-adrenoceptor blocking drugs" href="PHP934-beta-adrenoceptor-blocking-drugs.htm">section 2.4</a>) are of value in any grade of stable heart failure due to left ventricular systolic dysfunction; nebivolol (<a title="monograph: NEBIVOLOL" href="PHP1003-nebivolol.htm">section 2.4</a>) is licensed for stable mild to moderate heart failure in patients over 70 years. Beta-blocker treatment should be started by those experienced in the management of heart failure, at a very low dose and titrated very slowly over a period of weeks or months. Symptoms may deteriorate initially, calling for adjustment of concomitant therapy.</p><p>The aldosterone antagonist <strong>spironolactone</strong> can be added to an ACE inhibitor and a beta-blocker in patients who continue to remain symptomatic (particularly in those with moderate to severe heart failure); low doses of spironolactone (<a title="BNF:monograph: SPIRONOLACTONE" href="PHP834-spironolactone.htm">section 2.2.3</a>) reduce symptoms and mortality in these patients. If spironolactone cannot be used, eplerenone (<a title="monograph: EPLERENONE" href="PHP831-eplerenone.htm">section 2.2.3</a>) may be considered for the management of heart failure after an acute myocardial infarction with evidence of left ventricular systolic dysfunction. Close monitoring of serum creatinine, eGFR, and potassium is necessary, particularly following any change in treatment or any change in the patient's clinical condition.</p><p>Patients who cannot tolerate an ACE inhibitor or an angiotensin-II receptor antagonist, or in whom they are contra-indicated, may be given <strong>isosorbide dinitrate</strong> (<a href="PHP1256-nitrates.htm">section 2.6.1</a>) with <strong>hydralazine</strong> (<a title="sub-section: Vasodilator antihypertensive drugs" href="PHP1040-vasodilator-antihypertensive-drugs.htm">section 2.5.1</a>), but this combination may be poorly tolerated. The combination of isosorbide dinitrate and hydralazine may be considered in addition to standard therapy with an ACE inhibitor and a beta-blocker in patients who continue to remain symptomatic (particularly in patients of African or Caribbean origin who have moderate to severe heart failure).</p><p><strong>Digoxin</strong> (<a title="sub-section: Cardiac glycosides" href="PHP751-cardiac-glycosides.htm">section 2.1.1</a>) improves symptoms of heart failure and exercise tolerance and reduces hospitalisation due to acute exacerbations but it does not reduce mortality. Digoxin is reserved for patients with worsening or severe heart failure due to left ventricular systolic dysfunction who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker in combination with either an aldosterone antagonist, candesartan, or isosorbide dinitrate with hydralazine.</p><p>Patients with fluid overload should also receive either a loop or a thiazide diuretic (with salt or fluid restriction where appropriate). A <strong>thiazide diuretic</strong> (<a title="sub-section: Thiazides and related diuretics" href="PHP772-thiazides-and-related-diuretics.htm">section 2.2.1</a>) may be of benefit in patients with mild heart failure and good renal function; however, thiazide diuretics are ineffective in patients with poor renal function (eGFR less than 30 mL/minute/1.73 m<sup>2</sup>, see Renal Impairment, <a title="BNF:target-block: Thiazide and related diuretics and renal impairment" href="PHP772-thiazides-and-related-diuretics.htm#PHP776">section 2.2.1</a>) and a <strong>loop diuretic</strong> (<a href="PHP805-loop-diuretics.htm">section 2.2.2</a>) is preferred. If diuresis with a single diuretic is insufficient, a combination of a loop diuretic and a thiazide diuretic may be tried; addition of metolazone (<a title="sub-section: Thiazides and related diuretics" href="PHP772-thiazides-and-related-diuretics.htm">section 2.2.1</a>) may also be considered but the resulting diuresis may be profound and care is needed to avoid potentially dangerous electrolyte disturbances.</p></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">Previous: 2.5.5 Drugs affecting the renin-angiotensin system</a> | <a class="top" href="PHP1123-heart-failure.htm#">Top</a> | <a accesskey="]" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm">Next: 2.5.5.1 Angiotensin-converting enzyme inhibitors</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>